{
  "event_id": "410b605cf8e6",
  "ticker": "RETA",
  "company_name": "Reata Pharmaceuticals",
  "drug_name": "Bardoxolone",
  "pdufa_date": "2022-02-25",
  "approval_type": {
    "status": "found",
    "value": "nda",
    "source": "websearch:CARDINAL Phase 3 (CRL Feb 2022)",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.574862",
    "error": null
  },
  "indication": {
    "status": "found",
    "value": "CKD due to Alport syndrome",
    "source": "websearch:CARDINAL Phase 3 (CRL Feb 2022)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.574863",
    "error": null
  },
  "generic_name": {
    "status": "not_searched",
    "value": null,
    "source": null,
    "confidence": 0.0,
    "evidence": [],
    "searched_sources": [],
    "last_searched": null,
    "error": null,
    "_reset_reason": "Was inferred from: comprehensive_mapping",
    "_reset_at": "2026-01-09T23:49:24.204703"
  },
  "therapeutic_area": {
    "status": "found",
    "value": "Nephrology",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T10:49:59.039887",
    "error": null
  },
  "phase": {
    "status": "found",
    "value": "Phase 3",
    "source": "derived_from_result",
    "confidence": 0.95,
    "tier": 1,
    "searched_sources": [
      "result_field"
    ],
    "last_searched": null,
    "error": null
  },
  "primary_endpoint_met": {
    "status": "found",
    "value": false,
    "source": "websearch:CARDINAL Phase 3 (CRL Feb 2022)",
    "confidence": 0.3,
    "evidence": [
      "CARDINAL Phase 3 (CRL Feb 2022)"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.574842",
    "error": null
  },
  "p_value": {
    "status": "not_applicable",
    "value": null,
    "source": "websearch:CARDINAL Phase 3 (CRL Feb 2022)",
    "confidence": 0.9,
    "evidence": [
      "Single-arm or accelerated approval - no comparator p-value"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.574856",
    "error": null
  },
  "p_value_numeric": null,
  "effect_size": {
    "status": "found",
    "value": "eGFR improvement disputed by FDA",
    "source": "websearch:CARDINAL Phase 3 (CRL Feb 2022)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.574858",
    "error": null
  },
  "safety_signal": {
    "status": "found",
    "value": false,
    "source": "derived_from_crl_reason",
    "confidence": 0.85,
    "tier": 2
  },
  "phase3_study_names": [
    "An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients With Chronic Kidney Disease",
    "Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)",
    "A 52-Week, Multi-center, Double-blind, Randomized, Placebo-controlled Phase IIb Trial to Determine the Effects of Bardoxolone Methyl (RTA 402) on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease With an eGFR of 20 - 45 mL/Min/1.73m2",
    "RTA 402 Phase 2 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Chronic Kidney Disease and Type 2 Diabetes)",
    "A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome"
  ],
  "nct_ids": [
    "NCT03749447",
    "NCT01351675",
    "NCT00811889",
    "NCT02316821",
    "NCT03019185"
  ],
  "enrollment": {
    "count": 2185,
    "type": "ACTUAL",
    "nct_id": "NCT01351675",
    "source": "clinicaltrials.gov",
    "fetched_at": "2026-01-10T17:29:52.668667"
  },
  "has_prior_crl": {
    "status": "found",
    "value": true,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "prior_crl_reason": {
    "status": "found",
    "value": "ADCOM voted 13-0 against, efficacy concerns",
    "source": "web_search",
    "category": "CLINICAL_DATA",
    "confidence": 0.9,
    "tier": 2
  },
  "is_resubmission": {
    "status": "found",
    "value": 1,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "pai_passed": {
    "status": "found",
    "value": true,
    "source": "derived_from_crl_reason",
    "confidence": 0.85,
    "tier": 2
  },
  "warning_letter": {
    "status": "found",
    "value": false,
    "source": "derived_from_crl_reason",
    "confidence": 0.75,
    "tier": 2
  },
  "result": "crl",
  "data_quality_score": 0.15,
  "collected_at": "2026-01-09T00:32:24.233424",
  "enriched_at": "2026-01-11T20:06:06.902999",
  "needs_manual_review": false,
  "review_reasons": [],
  "original_case_id": "782846cb51c6",
  "fda_designations": {
    "breakthrough_therapy": true,
    "fast_track": true,
    "priority_review": true,
    "orphan_drug": true,
    "accelerated_approval": false
  },
  "mechanism_of_action": "Nrf2 activator",
  "adcom_info": {
    "scheduled": false,
    "held": false,
    "outcome": null,
    "vote": "0-13 against"
  },
  "days_to_pdufa": -1415,
  "pdufa_status": "past",
  "risk_tier": "HIGH",
  "days_calculated_at": "2026-01-10T16:59:41.780903",
  "adcom_scheduled": {
    "value": false,
    "status": "confirmed_none",
    "source": "websearch_adcom",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:44:22.947257"
  },
  "adcom_vote_ratio": {
    "value": null,
    "status": "not_applicable",
    "source": "websearch_adcom",
    "confidence": 0.6,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:44:22.947265"
  },
  "breakthrough_therapy": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:05:47.466534",
    "search_status": "CONFIRMED_NONE"
  },
  "orphan_drug": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:05:52.257109",
    "search_status": "CONFIRMED_NONE"
  },
  "priority_review": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:05:57.244579",
    "search_status": "CONFIRMED_NONE"
  },
  "fast_track": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:06:02.140968",
    "search_status": "CONFIRMED_NONE"
  },
  "accelerated_approval": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:06:06.902980",
    "search_status": "CONFIRMED_NONE"
  }
}